Search alternatives:
values decrease » values increased (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
Showing 8,741 - 8,760 results of 9,232 for search '(( i ((values decrease) OR (larger decrease)) ) OR ( a ((mean decrease) OR (linear decrease)) ))', query time: 0.68s Refine Results
  1. 8741

    Table 2_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  2. 8742

    Table 4_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  3. 8743

    Supplementary file 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  4. 8744

    Table 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  5. 8745

    Table 3_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  6. 8746

    <b>Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow up: Relation to Dysglycemia</b> by Nelly Mauras (8103110)

    Published 2025
    “…<p dir="ltr">Type 1 diabetes has detrimental effects in white matter microstructure. In a longitudinal study, we investigated if these reported findings change as children grow and enter puberty.…”
  7. 8747

    Table 1_Effect of cholecalciferol on immune and vascular function in non-diabetic chronic kidney disease.docx by Kajal Kamboj (12769602)

    Published 2025
    “…</p>Results<p>In total, 62 subjects were studied. The mean age was 44 ± 12 years with 58% men. TH1 cells decreased from 17% (9%, 27%) to 11% (6%, 16%) (p=0.002) and TH2 cells increased from 9% (5%, 16%) to 16% (10%, 27%) (p=0.001) after cholecalciferol treatment. …”
  8. 8748
  9. 8749

    Supplementary Material for: Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phas... by figshare admin karger (2628495)

    Published 2025
    “…Vitamin K concentration (contained less in OPF-109) was over the normal range on Day1 in both groups and decreased to slightly higher than the normal range in the OPF-109 group while increased to higher than Day1 value in the control group on Day8. …”
  10. 8750

    Table 1_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx by Deeksha Padhiar (21010250)

    Published 2025
    “…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”
  11. 8751

    <b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Cli... by Ellen M. Apperloo (20405468)

    Published 2025
    “…</p><p dir="ltr"><i>Conclusions:</i> In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.…”
  12. 8752

    Table 2_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx by Deeksha Padhiar (21010250)

    Published 2025
    “…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”
  13. 8753

    Supplementary file 1_Therapeutic efficacy and safety of Xuebijing in traumatic brain injury: systematic review and meta-analysis.docx by Yihan Sun (3432287)

    Published 2025
    “…Background<p>Traumatic brain injury (TBI) represents a major global health challenge. Several clinical studies have suggested that Xuebijing (XBJ)—a patented Chinese botanical drug preparation may confer neuroprotective and anti-inflammatory benefits in TBI. …”
  14. 8754

    Baseline characteristics of the study population. by Vatsala Rajendram (20691806)

    Published 2025
    “…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”
  15. 8755

    Patient disposition. by Vatsala Rajendram (20691806)

    Published 2025
    “…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”
  16. 8756

    Table 1_Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.docx by Zhifei Chen (1740625)

    Published 2025
    “…Participants were recruited from December 2021 to June 2022, with a follow-up period of 180 days. We evaluated humoral immune responses and their longevity by measuring the geometric mean titers (GMTs) of neutralizing antibodies against the SARS-CoV-2 virus at various time points post-boost. …”
  17. 8757
  18. 8758
  19. 8759

    Table 2_An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.xlsx by Jingkai Di (17792116)

    Published 2025
    “…Background<p>Nucleoside and nucleotide analogs are one of the mainstays of treatment for chronic hepatitis B, but their effects on bone density are highly controversial.…”
  20. 8760

    Table 3_An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.xlsx by Jingkai Di (17792116)

    Published 2025
    “…Background<p>Nucleoside and nucleotide analogs are one of the mainstays of treatment for chronic hepatitis B, but their effects on bone density are highly controversial.…”